Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN65,1165,142,13
Msft-0,17
Nokia3,29053,2965-1,02
IBM0,08
Mercedes-Benz Group AG73,8573,870,39
PFE-0,11
29.03.2024 0:37:52
Indexy online
AD Index online
select
AD Index online
 

  • 28.03.2024 21:30:00
ADMA Biologics (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
6,60 -2,08 -0,14 5 255 978
After-hours29.03.2024 0:05:06
Poslední obchod Nákup / Prodej Změna (%) Změna (USD)
6,56 - - -2,08 -0,14
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 29.03.2024
Popis společnosti
Obecné informace
Název společnostiADMA Biologics Inc
TickerADMA
Kmenové akcie:Ordinary Shares
RICADMA.O
ISINUS0008991046
Prioritní akciePreferred Shares
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky31.12.2023
Počet zaměstnanců k 31.12.2023 624
Akcie v oběhu k 23.02.2024 228 220 236
MěnaUSD
Kontaktní informace
UliceC/O Adma Biologics
MěstoRAMSEY
PSČ07446
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon12 014 785 552
Fax12014785553

Business Summary: ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, ADMA Biologics Inc revenues increased 68% to $258.2M. Net loss decreased 57% to $28.2M. Revenues reflect ADMA BioManufacturing segment increase of 73% to $249.7M, Corporate segment remaining flat at $143K, United States segment increase of 67% to $244.9M, International segment increase of 74% to $13.3M.
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Biopharmaceuticals
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSBiological Product (except Diagnostic) Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NAICS2007Biological Product (exc Diagnostic) Mfg
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS1997Biological Product (except Diagnostic) Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICBiological Prod's Not Diagnostic
SICBiological Prod's Not Diagnostic
SICCommercial Physical Research



  • Poslední aktualizace: 29.03.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, Co-Founder, DirectorAdam Grossman4601.01.2007
Vice Chairman of the Board, Co-FounderJerrold Grossman75
Chief Financial Officer, Executive Vice PresidentBrian Lenz5022.06.201801.05.2012